Compounded GLP-1 telehealth grew rapidly through 2024 and 2025 as branded semaglutide and tirzepatide faced supply shortages and high out-of-pocket costs, and the FDA has continued active enforcement in this space through 2026, including a public warning-letter action against a group of telehealth companies over misleading marketing claims tied to compounded GLP-1 products
It is important to evaluate all potential vendors on criteria like quality assurance, pricing and discounts, customer service, and shipping speed
For women experiencing Hypoactive Sexual Desire Disorder (HSDD), reduced satisfaction, or wanting to enhance intimate experiences PT-141 was specifically developed and FDA-approved for this purpose in premenopausal women
Fan H, Gong N, Li TF, Ma AN, Wu XY, Wang MW, Wang YX (2015) The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating beta-endorphin release from spinal microglia